Related Experiment Video
Updated: Jan 7, 2026
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Biomarkers
1University of Glasgow, Glasgow, Glasgow, United Kingdom.
Insights
Cardiovascular disease risk and blood biomarkers for Alzheimer's disease (AD) are linked to cognitive impairment (CI). However, cardiovascular disease risk does not moderate the association between these biomarkers and CI, suggesting independent risk factors.
Area of Science:
- Neurology
- Biomarker Research
- Cardiovascular Health
Background:
- Blood-based biomarkers offer potential for revolutionizing Alzheimer's disease (AD) diagnosis and prognosis.
- Cardiovascular disease (CVD) risk factors like hypertension and diabetes are associated with cognitive impairment (CI) and dementia.
- The interplay between CVD risk and blood-based AD biomarkers in relation to CI requires further investigation.
Purpose of the Study:
- To investigate whether CVD risk significantly moderates the relationship between blood-based AD biomarkers and CI.
- To explore the independent and combined effects of CVD risk and AD biomarkers on cognitive function.
Main Methods:
- Included 661 participants (395 CI, 266 cognitively normal) from the Bio-Hermes study.
- Calculated CVD risk using the Atherosclerotic CVD (ASCVD) risk score.
- Performed logistic regression analyses for AD biomarkers (Aβ42/Aβ40, p-tau181, p-tau217, Apoε4) and CVD risk, testing for moderation by CVD risk.
Main Results:
- Both blood-based biomarkers and CVD risk were significantly associated with CI.
- Plasma p-tau217 showed the strongest association with CI (OR=2.34).
- CVD risk moderated the relationship between p-tau181 and CI, but not for other biomarkers.
Conclusions:
- Blood-based dementia biomarkers and CVD risk are independently associated with CI.
- CVD risk assessment should complement dementia biomarker evaluations for accurate prognosis.
- Understanding multiple risk factors is crucial given the global impact of dementia.
Background:
Blood-based biomarkers show great promise to revolutionize diagnosis and prognosis of Alzheimer's disease (AD) and other dementias. Cardiovascular disease (CVD) risk factors, such as hypertension and diabetes, contribute to risk of cognitive impairment (CI), vascular and Alzheimer's disease dementia. The relationship between CVD risk and blood-based biomarkers for AD remains unclear. We sought to explore whether CVD risk significantly moderates the relationship between blood-based AD biomarkers and CI.
Method:
We included participants with mild cognitive impairment or probable AD (CI group), versus cognitively normal comparators (CN) from the Bio-Hermes study. Clinical presentation of CI was determined based on clinical screening procedures. CVD risk was calculated using the Atherosclerotic CVD (ASCVD) risk score calculator. We conducted a series of logistic regression analyses to evaluate the association of each of several AD biomarkers (plasma amyloid beta (Aβ) 42/Aβ40, phosphorylated tau (p-tau)181, p-tau217, apolipoprotein E ε4 allele (Apoε4) status) and CVD risk, with CI. We then tested moderation by CVD risk in each model.
Result:
We included 661 participants (n = 266 CN, n = 395 CI; mean age 72.4 years; 55% male). In each of the models, blood-based biomarkers and CVD risk were significantly associated with CI. Strongest association was for p-tau217 (OR = 2.34 [95% CI:1.89-2.9]). CVD risk moderated the relationship between p-tau181 and CI (OR = 0.78 [95% CI: 0.64-0.95]) but no moderation effect was observed for any of the other biomarkers.
Conclusion:
In our study, blood-based dementia biomarkers and CVD risk significantly associated with CI, but CVD risk did not moderate the relationship between blood-based biomarkers and CI. Blood-based biomarkers and CVD risk might confer independent risk of CI. Given the multiple risk factors for dementia and large implications for social and healthcare systems globally, CVD risk assessment should complement other dementia biomarker assessments for accurate and expeditious prognosis.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...